Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now full pipeline small index

Cushing's Disease: full-pipeline trial registry

3 of 6 indexed Cushing's Disease trials are currently recruiting.

Corpus placement: #2,866 of 28,707 conditions by registered trial count.

6 US clinical trials · 3 currently recruiting · #2,866 of 28,707 conditions by registered trial count

Cushing's Disease: 6 US clinical trials tracked, 3 recruiting.

Cushing's Disease is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Novartis Pharmaceuticals, running 3 of these trials.

Enrollment posture brief

Registry condition cushings-disease

OPEN 3 | RECR 50% | LATE 2 | EARLY 2 | RANK #2866 | SPON 3

Nearest open-share peer: Achalasia (50% recruiting · 8 trials)

Acute Hypoxemic Respiratory 66.7%Abdominal Aortic Aneurysms50%Acupuncture50%Acute Lymphoblastic Leukemia50%Cushing's Disease (this)50%
Open-enrollment share among volume-matched conditions near Cushing's Disease

Cushing's Disease lists 3 open slots (50% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Cushing's Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Cushing's Disease is recruiting above its size-band peers.

    3 of 6 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Cushing's Disease research.

    Novartis Pharmaceuticals accounts for 3 of 6 trials (50%). 4 distinct sponsors appear on at least one study for this condition label.

  3. Typical Cushing's Disease enrolment sits around 137 participants.

    Median target enrolment is 137 among the 6 trials that report a genuine target (sentinel values excluded). 3 of those (50%) plan for fewer than 100 participants.

  4. Cushing's Disease research is mostly interventional.

    5 interventional and 1 observational studies make up this index (83.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 22Phase 32

Phase Distribution

PhaseTrial count
Phase 2 2
Phase 3 2

Named interventions

Most-linked intervention names on Cushing's Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

SOM230 LAR 10 mg Drug
1 trials
SOM230 LAR 30 mg Drug
1 trials
pasireotide LAR Drug
1 trials
LCI699 matching placebo Drug
1 trials
osilodrostat Drug
1 trials
LCI699 Drug
1 trials
Desmopressin acetate Drug
1 trials
Lu AG13909 Drug
1 trials

US sites by state

Facility locations filed on Cushing's Disease trials. A trial with sites in several states counts in each.

Oregon 3 trials
New York 3 trials
Michigan 3 trials
Maryland 3 trials
Wisconsin 2 trials
Pennsylvania 2 trials
Massachusetts 2 trials
Illinois 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Cushing's Disease page

6 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cushing's Disease condition card totals 6 registered trials; most-linked intervention SOM230 LAR 10 mg; top US site state Oregon. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.